Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ: ALKS )

34.23 +0.61 (+1.80%)
Streaming Delayed Price Updated: 11:02 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Alkermes: Diversity Strengthens Our Culture
SOURCE: Alkermes 
Via 3BL Media
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award
SOURCE: Alkermes 
Via 3BL Media
Alkermes Supports Mental Health Clinical Research
SOURCE: Alkermes 
Via 3BL Media
"I'm Incredibly Proud to Work at a Company Whose Mission Is To Help Families Like Mine"
SOURCE: Alkermes 
Via 3BL Media
Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med
The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Are You Thinking About Your Alcohol Drinking Habits?
SOURCE: Alkermes 
Via 3BL Media
Alkermes Celebrates World Health Day 2021
SOURCE: Alkermes 
Via 3BL Media
Alkermes Inspiration Grants® 2021 Applications Are Now Open
SOURCE: Alkermes 
Via 3BL Media
Alkermes Celebrates Mental Health Month
SOURCE: Alkermes 
Via 3BL Media
Exposures COVID-19
Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
SOURCE: Alkermes 
Via 3BL Media
Why Shares of Alkermes Rose 18% Last Month
An agreement with an activist investor capped a busy month. 
Via The Motley Fool
Want to Make Money in Biotech? Do This First
Keeping track of upcoming events is important. 
Via The Motley Fool
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
SOURCE: Alkermes 
Via 3BL Media
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Alkermes PLC (ALKS) Q1 2021 Earnings Call Transcript
ALKS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence
SOURCE: Alkermes 
Via 3BL Media
Alkermes: Q1 Earnings Insights
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11,... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy
Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma... 
Via Benzinga
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
SOURCE: Alkermes 
Via 3BL Media
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
This Alcohol Awareness Month, Reevaluate Your Relationship With Alcohol
SOURCE: Alkermes 
Via 3BL Media
Exposures COVID-19
Alkermes Shares Immuno Oncology Clinical Trial Research
SOURCE: Alkermes 
Via 3BL Media
Alkermes Celebrates National Minority Health Month
SOURCE: Alkermes 
Via 3BL Media
Alkermes Provides Resources for Talking to a Loved One About Alcohol Dependence
SOURCE: Alkermes 
Via 3BL Media
How Posting About Alcohol May Be Hurting Those Having Trouble Coping With the Pandemic
SOURCE: Alkermes 
Via 3BL Media
Exposures COVID-19
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.